APA (7th ed.) Citation

CR, C., B, C., D, T., LC, P., R, B., KE, H., . . . F, U. (2020). Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes. British journal of haematology, 189(5), e211. https://doi.org/10.1111/bjh.16629

Chicago Style (17th ed.) Citation

CR, Cogle, et al. "Safety, Feasibility and Preliminary Efficacy of Single Agent Combretastatin A1 Diphosphate (OXi4503) in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes." British Journal of Haematology 189, no. 5 (2020): e211. https://doi.org/10.1111/bjh.16629.

MLA (9th ed.) Citation

CR, Cogle, et al. "Safety, Feasibility and Preliminary Efficacy of Single Agent Combretastatin A1 Diphosphate (OXi4503) in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes." British Journal of Haematology, vol. 189, no. 5, 2020, p. e211, https://doi.org/10.1111/bjh.16629.